6 Ways to Lower Your Cancer Risk
“An estimated 2 million Americans were diagnosed with cancer in 2023, and more than 600,000 died from the disease. According to the American Association for Cancer Research, more than 40% of those cases and nearly half of the deaths can be attributed to preventable causes such as smoking, obesity and excessive exposure to the sun. February is National Cancer Prevention Month. It’s the perfect time to evaluate your lifestyle and make health a priority.”
Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
“AUSTIN, Texas, Feb. 5, 2024 /PRNewswire/ — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that in January 2024, the first patient was enrolled and dosed in the Phase 2a expansion portion of the Company’s Acclaim-1 clinical study of Reqorsa® Therapy (quaratusugene ozeplasmid) in combination with AstraZeneca’s Tagrisso® to treat patients with late-stage non-small cell lung cancer (NSCLC).”
Dynamic phenotypic reprogramming and chemoresistance induced by lung fibroblasts in small cell lung cancer
“Small cell lung cancer (SCLC) is heterogenous in phenotype and microenvironment. Dynamic phenotypic reprogramming, leading to heterogeneity, is prevalent in SCLC, while the mechanisms remain incompletely understood. Cancer-associated fibroblasts (CAFs) possess comprehensive roles in cancer progression, while their function in phenotypic reprogramming of SCLC remain elusive.”
Global Cancer Burden May Be Growing Amidst Mounting Need for Cancer Services
“The World Health Organization’s (WHO) cancer agency, the International Agency for Research on Cancer (IARC), has released updated findings of the current global burden of cancer alongside World Cancer Day on February 4, 2023. The WHO indicated that a majority of countries do not adequately finance priority cancer and palliative care services as part of universal health coverage. Lung cancer was also the leading cause of cancer mortality with 1.8 million deaths accounting for 18.7% of the total cancer deaths, followed by colorectal cancer (900,000 deaths, 9.3%), hepatic cancer (760,000 death, 7.8%), breast cancer (670,000 deaths, 6.9%), and gastric cancer (660,000 deaths, 6.8%). Lung cancer’s reemergence as the most common cancer type may have been related to the persistent use of tobacco across Asian countries.”
Cancer vaccine being trialled by NHS may herald ‘dawn of a new age’ of treatments
“Two decades of work in the field of cancer vaccines finally starting to bear fruit, experts say”
Lung Cancer Screening and Stigma: Do Smoking-related Differences in Perceived Lung Cancer Stigma Emerge Prior to Diagnosis?
“Conclusions: Sociodemographic variables (rather than smoking-related characteristics) significantly and uniquely differentiated lung cancer screening-eligible adults’ perception of lung cancer stigma. Smoking-related differences in lung cancer stigma may emerge following rather than prior to diagnosis.”
Circ0087385 promotes DNA damage in benzo(a)pyrene-induced lung cancer development by upregulating CYP1A1
“Increasing environmental genotoxic chemicals have been shown to induce epigenetic alterations. However, the interaction between genetics and epigenetics in chemical carcinogenesis is still not fully understood. Here, we constructed an in vitro human lung carcinogenesis model (16HBE-T) by treating human bronchial epithelial cells with a typical significant carcinogen benzo(a)pyrene (BaP).”
Withdrawal of ‘lifeline’ lung cancer drug to be debated in House of Lords
“Ulster Unionist peer Lord Rogan has secured a short debate on the floor of the House of Lords next week (Wednesday 14 February) following the announcement that Takeda Pharmaceuticals is voluntarily withdrawing the drug Mobocertinib for the UK market despite it being a critical lifeline for EGFR positive lung cancer patients.”
Osimertinib May Offer Survival Benefit Over Immunotherapy in Some Patients With Unresectable NSCLC
“Investigators have found that the targeted therapy osimertinib may be associated with improved progression-free survival when administered after chemotherapy and radiation in patients with non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, according to a recent study published by Nassar et al in the Journal of Thoracic Oncology.”
Bevacizumab Combo Does Not Improve Outcomes in Metastatic Nonsquamous NSCLC
“Bevacizumab (Avastin) plus atezolizumab (Tecentriq), carboplatin, and pemetrexed did not result in significantly improved clinical outcomes compared with atezolizumab plus carboplatin and pemetrexed alone in patients with advanced nonsquamous non–small cell lung cancer (NSCLC), according to findings from a phase 3 trial (jRCT2080224500) published in JAMA Oncology.”
Combining genomic biomarkers to guide immunotherapy in non-small cell lung cancer
“Purpose: The clinical value of STK11, KEAP1 and EGFR alterations for guiding immune checkpoint blockade (ICB) therapy in non-small cell lung cancer (NSCLC) remains controversial, as some patients with these proposed resistance biomarkers show durable ICB responses. More specific combinatorial biomarker approaches are urgently needed for this disease.”
Video:
Person-First Language May Mitigate Stigmatization in Lung Cancer Screening
“It is crucial to use person-first language to reduce potential feelings of stigmatization around lung cancer diagnoses and ensure that patients are receiving equitable treatment across the board, according to Lisa Carter-Bawa PhD, MPH, APRN, ANP-C, FAAN.”
Dr Curran on Developing Strategies for Stage III NSCLC Management
“Wally Curran, MD, chief, Piedmont Oncology Institute, discusses current and developing treatment strategies for patients with stage III unresectable non–small cell lung cancer (NSCLC).”
Dr Halmos on Treatment Strategies For EGFR-Mutant NSCLC
“Balazs Halmos, MD, professor, Department of Oncology (Medical Oncology), professor, Department of Medicine (Oncology & Hematology), associate director, Clinical Science, Montefiore Einstein Comprehensive Cancer Center, discusses treatment strategies for patients with EGFR-mutant non–small cell lung cancer (NSCLC).”
